Table 1.
Patient characteristics
| Lapatinib plus bevacizumab | |
|---|---|
| (N = 52) | |
| Median age, years | 52.0 |
| Race, n (%) | |
| White | 42 (81) |
| African American | 7 (13) |
| Asian | 3 (6) |
| Stage IV, n (%) | 52 (100) |
| HER2 FISH+ or IHC 3+ (local), n (%) | 51 (98)a |
| ECOG 0/1, n (%) | 28 (54)/24 (46) |
| Visceral ± nonvisceral sites, n (%) | 43 (83) |
| ER/PR status, n (%) | |
| ER-/PR- | 26 (50) |
| ER+/PR any | 26 (50) |
| Prior chemotherapy regimens in the metastatic setting, n (range) | 3 (0–12) |
| Prior trastuzumab therapy, n (%) | 47 (90) |
| Neoadjuvant | 2 (4) |
| Adjuvant | 7 (13) |
| Metastatic | 42 (89) |
| Median duration of prior trastuzumab, weeks (range) | 84.1 (5.3–434.3) |
| Neoadjuvant | 8.1 (2.1–14.0) |
| Adjuvant | 12.0 (6.1–151.0) |
| Metastatic | 84.1(5.3–434.3) |
| Prior lapatinib in the metastatic setting, n (%) | 11 (21) |
| Median treatment duration, weeks (range) | 30.7 (3.3–52.3) |
| Prior hormonal therapy, n (%) | 27 (52) |
HER2 human epidermal growth factor receptor-2, FISH+ fluorescence in situ hybridization-positive, IHC immunohistochemistry, ECOG Eastern cooperative oncology group, ER- estrogen receptor-negative, PR- progesterone receptor-negative, ER+ estrogen receptor-positive
aFISH results not available for one IHC 1+ patient who received >2 years of prior trastuzumab and lapatinib; this patient progressed on day 38